2Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology, 2007, 45: 1056-1075.
3Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol, 2007, 5: 890-897.
4Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology, 2007, 46: 254-265.
5Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology, 2008, 134: 405-415.
6Lok AS. I-IBV treatment in dications and efficacy of approved nucleoside/nucleotide inhibitors//EASL-AASLD-APASL-ALEH-IASL Conference: hepatitis B and C virus resistance to antiviral therapies, Pads, 2008. http://www.easl.ch/hepatitis-conference.
3Shimoda M, Iwasaki Y, Okada T, et al. Protective effect of Sivelestat in a porcinehepatectomy model pre- pared using an intermittentPringle method[J]. Eur J Pharmacol, 2008,587 (1-3) : 248-252.
4Jansen MC, Wanrooy S, Hillegersberg R, et al. As- sessment of systemic inflammatory response(SIR) in patients undergoing radiofrequencyablation or partial liver resection for liver tumors [J]. Eur J Surg oncot, 2008,34(6) : 662-667.
